[go: up one dir, main page]

PE20051054A1 - Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento - Google Patents

Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Info

Publication number
PE20051054A1
PE20051054A1 PE2005000061A PE2005000061A PE20051054A1 PE 20051054 A1 PE20051054 A1 PE 20051054A1 PE 2005000061 A PE2005000061 A PE 2005000061A PE 2005000061 A PE2005000061 A PE 2005000061A PE 20051054 A1 PE20051054 A1 PE 20051054A1
Authority
PE
Peru
Prior art keywords
alkyl
growth hormone
ilmethyl
pyrrolidin
compounds
Prior art date
Application number
PE2005000061A
Other languages
English (en)
Inventor
Weixu Zhai
Samuel Gerritz
Andres
Joseph A Tino
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20051054A1 publication Critical patent/PE20051054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I); EN DONDE R1 ES H, ALQUILO, ARILO, OXIALQUILO, OXIPERFLUOROALQUILO, AMINOCARBOALQUILO, OPCIONALMENTE SUSTITUIDOS; R2 ES H O ALQUILO; R3 ES H, ALQUILO, HALO; R4 ES H O ALQUILO; X ES (CH2)n, DONDE n ES 0 A 1. SON COMPUESTOS PREFERIDOS: 2-3(-CLOROFENOXI-N-(2-CLOROBENCIL)-N-(R-)-PIRROLIDIN-2-ILMETIL-PROPIONAMIDA, N-(4-ACETILAMINO-FENIL)-2-(3-CLOROFENOXI-N-.(R)-PIRROLIDIN-2-ILMETIL-PROPIONAMIDA, N-BENCIL-2-FENOXI-N-(R)-PIRROLIDIN-2-ILMETIL-BUTIRAMIDA, ENTRE OTROS. ESTOS COMPUESTOS SON SEGRETAGOGOS DE LA HORMONA DE CRECIMIENTO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ADEMAS PUEDEN COMPRENDER OTRO AGENTE ACTIVO COMO OTRO COMPUESTO DE FORMULA (I), HORMONA PARATIROIDES, BISFOSFONATOS, ESTROGENO, TESTOSTERONA, MODULADORES DEL RECEPTOR DE ESTROGENO SELECTIVO, ENTRE OTROS. SON UTILES PARA EL TRATAMIENTO DE LOS TRANSTORNOS ASOCIADOS CON LOS NIVELES DE LA HORMONA DE CRECIMIENTO COMO ATROFIA MUSCULAR, LIPODISTROFIA, ENTRE OTROS
PE2005000061A 2004-01-13 2005-01-13 Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento PE20051054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53612804P 2004-01-13 2004-01-13

Publications (1)

Publication Number Publication Date
PE20051054A1 true PE20051054A1 (es) 2005-12-16

Family

ID=34806987

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000061A PE20051054A1 (es) 2004-01-13 2005-01-13 Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Country Status (5)

Country Link
US (1) US7214804B2 (es)
AR (1) AR047382A1 (es)
PE (1) PE20051054A1 (es)
TW (1) TW200530181A (es)
WO (1) WO2005070884A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
EP1931199A4 (en) * 2005-08-31 2009-07-29 Univ Tennessee Res Foundation COMBATING NURSE DISEASE, BURNS, WOUNDS AND BACKMARK INJURIES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
EA019849B1 (ru) * 2006-08-28 2014-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
ES2413504T3 (es) 2007-12-21 2013-07-16 Ligand Pharmaceuticals Inc. Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
IN2015DN01046A (es) 2012-07-13 2015-06-26 Gtx Inc
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
BR112021020864A2 (pt) 2019-04-19 2021-12-14 Ligand Pharm Inc Formas cristalinas e métodos de produção de formas cristalinas de um composto
EP4294523A4 (en) * 2021-02-18 2025-01-08 X-Biotix Therapeutics, Inc. Arylthioether acetamide and related compounds and their use in treating medical conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues

Also Published As

Publication number Publication date
WO2005070884A3 (en) 2006-05-26
US20050154043A1 (en) 2005-07-14
TW200530181A (en) 2005-09-16
AR047382A1 (es) 2006-01-18
WO2005070884A2 (en) 2005-08-04
US7214804B2 (en) 2007-05-08

Similar Documents

Publication Publication Date Title
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20211810A1 (es) Compuestos novedosos
PE20051051A1 (es) Compuestos de triazol como antagonistas de la vasopresina
PE20090772A1 (es) Derivados de bencimidazol
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
ATE384058T1 (de) Thiazolderivate
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20231746A1 (es) Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
PE20030944A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
PE20061295A1 (es) Derivados de acetileno
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
PE20061049A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida como antagonistas del receptor de vanilloides tipo 1 (vr1)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal